Investor News

Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases

Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced today that it has been awarded a €1.7 million grant from the Flemish Agency for Innovation and Entrepreneurship (VLAIO). The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates. 

Through its unique platform technology, Confo Therapeutics develops GPCR modulators for patients with severe and underserved diseases, with a specific focus on rare diseases. Among other things, the company intends to address an important target for neurological orphan conditions which is currently considered to be an undruggable GPCR.

The research pursued under the aegis of this VLAIO grant will allow Confo Therapeutics to unlock new potential treatments for unmet disease areas and to simultaneously pursue new technology developments. This should ultimately shorten drug discovery timelines and expand their proprietary pipeline for rare disease indications. ​

Share

Latest stories

Website preview
How plants keep their root hairs alive and why that matters for crop resilience
Ghent, Belgium – 12 May 2026. Plants rely on millions of tiny hairs on their roots to absorb water and nutrients from the soil. Now, a research team at VIB and UGent led by Prof. Moritz Nowack, has discovered that the lifespan of these root hairs is governed by a surprisingly precise molecular balancing act between recycling and cell death. The findings, published in Nature Plants, open new avenues for engineering crops that are better at extracting resources from the soil.
press.vib.be
Website preview
Plants survived the dinosaur-killing asteroid by duplicating genomes
Ghent, 8 May 2025 – When an asteroid as big as Mount Everest struck Earth 66 million years ago, it wiped out all non-avian dinosaurs and roughly a third of life on the planet. But many plants survived the devastation. In a new study in Cell, researchers from VIB and Ghent University reveal that the accidental duplications of genomes might have helped many flowering plants survive some of the most extreme environmental upheavals in Earth’s history. This strategy could help plants adapt to the rapid climate changes unfolding today.
press.vib.be
Website preview
New research brings personalized treatment for Parkinson’s disease a step closer
Leuven, 5 May 2026 – A new study led by researchers from VIB and KU Leuven shows that Parkinson’s disease can be divided into distinct subtypes, helping explain why a single treatment does not work for all patients. Using an machine-learning-driven analysis, the team identified two main groups and five subgroups of the disease, marking an important step toward more personalized therapies. The findings were recently published in Nature Communications.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be